CY1113044T1 - Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων - Google Patents
Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτωνInfo
- Publication number
- CY1113044T1 CY1113044T1 CY20121100353T CY121100353T CY1113044T1 CY 1113044 T1 CY1113044 T1 CY 1113044T1 CY 20121100353 T CY20121100353 T CY 20121100353T CY 121100353 T CY121100353 T CY 121100353T CY 1113044 T1 CY1113044 T1 CY 1113044T1
- Authority
- CY
- Cyprus
- Prior art keywords
- psca
- cell
- subsequents
- protector
- external antigen
- Prior art date
Links
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 title abstract 6
- 102100036735 Prostate stem cell antigen Human genes 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000284 extract Substances 0.000 title 1
- 230000001012 protector Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Το ΡSCΑ και η εγκωδικευθείσα πρωτεΐνη αυτού, και τα παραλλάγματα εξ αυτής, περιγράφονται όπου το ΡSCΑ εκδηλώνει ειδική των ιστών έκφραση σε φυσιολογικό ιστό ενηλίκων, και εκφράζεται παρεκκλινόντως στους καρκίνους που καταλογοποιούνται στον Πίνακα Ι. Επακόλουθα, το ΡSCΑ παρέχει έναν διαγνωστικό, προγνωστικό, προφυλακτικό και/ή θεραπευτικό στόχο για τον καρκίνο. Το γονίδιο του ΡSCΑ ή το θραύσμα εξ αυτού, ή η εγκωδικευθείσα πρωτεΐνη αυτού, ή τα παραλλάγματα εξ αυτής, ή ένα θραύσμα εξ αυτών, μπορεί να χρησιμοποιηθεί για να εκμαιεύσει μια χυμική ή κυτταρική ανοσιακή απόκριση• τα αντισώματα ή τα Τ κύτταρα που αντιδρούν με το ΡSCΑ μπορεί να χρησιμοποιηθούν σε ενεργητική ή παθητική ανοσοποίηση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47506403P | 2003-05-30 | 2003-05-30 | |
EP04785910A EP1629088B1 (en) | 2003-05-30 | 2004-05-28 | Prostate stem cell antigen (psca) variants and subsequences thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113044T1 true CY1113044T1 (el) | 2016-04-13 |
Family
ID=34135042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100353T CY1113044T1 (el) | 2003-05-30 | 2012-04-10 | Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων |
Country Status (24)
Country | Link |
---|---|
US (4) | US7622564B2 (el) |
EP (2) | EP2319524B1 (el) |
JP (1) | JP2007525196A (el) |
KR (1) | KR101291787B1 (el) |
CN (1) | CN101090729B (el) |
AT (1) | ATE541052T1 (el) |
AU (2) | AU2004263823B2 (el) |
BR (1) | BRPI0410842B8 (el) |
CA (1) | CA2526274C (el) |
CY (1) | CY1113044T1 (el) |
DK (2) | DK2319524T3 (el) |
ES (1) | ES2384622T3 (el) |
HK (1) | HK1088635A1 (el) |
IL (1) | IL171966A (el) |
IS (1) | IS2900B (el) |
MX (1) | MXPA05012957A (el) |
NO (1) | NO20055508L (el) |
NZ (3) | NZ572940A (el) |
PL (1) | PL1629088T3 (el) |
PT (1) | PT1629088E (el) |
RU (1) | RU2005141341A (el) |
SI (1) | SI1629088T1 (el) |
WO (1) | WO2005014780A2 (el) |
ZA (1) | ZA200509606B (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US7541442B2 (en) * | 2003-05-30 | 2009-06-02 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
ATE541052T1 (de) | 2003-05-30 | 2012-01-15 | Agensys Inc | Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon |
US7595379B2 (en) * | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
JP2008527001A (ja) * | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
CN101223191B (zh) * | 2005-04-14 | 2012-09-05 | 阿根西斯公司 | 与psca蛋白结合的抗体和相关分子 |
EP1874800A4 (en) * | 2005-04-26 | 2009-11-18 | Karyon Ctt Ltd | DIAGNOSTIC AND THERAPEUTIC AGENTS |
KR20080090406A (ko) * | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
WO2007086932A2 (en) * | 2006-01-13 | 2007-08-02 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
JP2009531324A (ja) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体 |
WO2008047300A2 (en) * | 2006-10-16 | 2008-04-24 | Nokia Corporation | System and method for using parallelly decodable slices for multi-view video coding |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
AU2008316224A1 (en) * | 2007-10-25 | 2009-04-30 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
CN104623664B (zh) * | 2008-11-11 | 2018-08-07 | 密歇根大学董事会 | 抗cxcr1组合物和方法 |
WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
KR101335203B1 (ko) * | 2010-03-26 | 2013-11-29 | 숙명여자대학교산학협력단 | 혈관신생촉진용 펩타이드 및 이의 용도 |
US8449512B2 (en) | 2010-04-09 | 2013-05-28 | Davinci Biomedical Research Products Inc. | Stoma stabilitating device and method |
AU2015261742B2 (en) * | 2010-11-12 | 2017-10-26 | Inovio Pharmaceuticals, Inc. | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
EP2638055B1 (en) | 2010-11-12 | 2019-01-09 | The Trustees Of The University Of Pennsylvania | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
US8928126B2 (en) * | 2012-11-07 | 2015-01-06 | United Microelectronics Corp. | Epitaxial layer |
MY182168A (en) * | 2013-11-01 | 2021-01-18 | Pfizer | Vectors for expression of prostate-associated antigens |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CA2976879A1 (en) | 2015-02-18 | 2016-08-25 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
KR20180110141A (ko) | 2016-02-18 | 2018-10-08 | 엔리벡스 테라퓨틱스 리미티드 | 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN106749674A (zh) * | 2016-12-23 | 2017-05-31 | 四川大学 | 一种新型哮喘多肽疫苗及其制备方法 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
CN111951887A (zh) * | 2020-07-27 | 2020-11-17 | 深圳市新合生物医疗科技有限公司 | 基于深度学习的白细胞抗原与多肽结合亲和力预测方法 |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506A (en) | 1848-04-11 | Jackson stjtton | ||
US5736A (en) | 1848-08-29 | Machinery fob dressing axes | ||
US28883A (en) | 1860-06-26 | James | ||
US337A (en) | 1837-07-31 | Mode of constructing railroad-frogs | ||
US142A (en) | 1837-03-11 | Cooking apparatus | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
EP0462145B1 (en) | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
JP3056782B2 (ja) | 1989-11-03 | 2000-06-26 | ヴァンダービルト ユニバーシティ | 標的器官内での遺伝子の発現用医薬組成物 |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
DE69132771T2 (de) | 1990-06-27 | 2002-08-01 | Princeton University Princeton | Sonden für die detektion der p53 mutante |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
SE9002480D0 (sv) | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
NZ255683A (en) | 1992-08-07 | 1996-08-27 | Cytel Corp | Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5559410A (en) | 1992-12-17 | 1996-09-24 | Valeo Systemes D'essuyage | Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield |
US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
DE69435292D1 (de) | 1993-03-05 | 2010-06-17 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden |
NZ267797A (en) | 1993-05-17 | 1997-09-22 | Univ California | Retroviral vector comprising a ribozyme capable of cleaving a hiv nucleic acid capable |
US5837501A (en) | 1993-07-09 | 1998-11-17 | Akzo Nobel N.V. | Nucleic acid quantitation by co-amplification of target with multiple internal controls |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
WO1996002561A1 (en) | 1994-07-20 | 1996-02-01 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US5585639A (en) | 1995-07-27 | 1996-12-17 | Hewlett-Packard Company | Optical scanning apparatus |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
JP2001504799A (ja) | 1996-03-11 | 2001-04-10 | エピミューン インコーポレイテッド | Hla分子への結合アフィニティーが増加したペプチド |
CA2252886C (en) | 1996-04-26 | 2008-02-12 | Massachusetts Institute Of Technology | Three-hybrid screening assay |
US5856136A (en) | 1996-07-03 | 1999-01-05 | Incyte Pharmaceuticals, Inc. | Human stem cell antigens |
WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
US6365797B1 (en) | 1997-10-15 | 2002-04-02 | The Regents Of The University Of California | Mice models of human prostate cancer progression |
ATE371721T1 (de) | 1996-10-15 | 2007-09-15 | Univ California | Tiermodelle für die menschliche prostatakrebsfortschreitung |
US5846722A (en) | 1996-10-16 | 1998-12-08 | Terrapin Technologies, Inc. | System to detect small molecule/peptide interaction |
US5840501A (en) | 1996-10-25 | 1998-11-24 | Bayer Corporation | Determination of cPSA |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
DE69824287T2 (de) | 1997-03-10 | 2005-06-16 | The Regents Of The University Of California, Oakland | Prostata stammzell-antigen (psca) |
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US6258939B1 (en) * | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
WO1998051805A1 (en) * | 1997-05-15 | 1998-11-19 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
WO1998051824A1 (en) | 1997-05-15 | 1998-11-19 | Abbott Laboratories | Reagents and methods useful for detecting disease of the urinary tract |
US20020192659A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030044839A1 (en) * | 1997-09-17 | 2003-03-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2303834A1 (en) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2004507201A (ja) * | 1998-09-16 | 2004-03-11 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードしている核酸 |
AU2883900A (en) * | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ATE400587T1 (de) * | 1999-10-29 | 2008-07-15 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
WO2003089575A2 (en) * | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
ATE541052T1 (de) * | 2003-05-30 | 2012-01-15 | Agensys Inc | Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon |
US7541442B2 (en) | 2003-05-30 | 2009-06-02 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
US7595379B2 (en) * | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
WO2005118864A2 (en) * | 2004-05-28 | 2005-12-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
AU2006237616B9 (en) | 2005-04-14 | 2012-12-06 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
TWI552751B (zh) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神***症的方法 |
KR102028770B1 (ko) | 2011-09-15 | 2019-10-04 | 컨버전트 인포메이션 테크놀로지스 게엠베하 | 로봇 프로그램의 자동 생성을 위한 시스템 및 방법 |
US9804664B2 (en) | 2014-05-27 | 2017-10-31 | Qualcomm Incorporated | Adaptive control of RF low power modes in a multi-rate wireless system using MCS value |
-
2004
- 2004-05-28 AT AT04785910T patent/ATE541052T1/de active
- 2004-05-28 DK DK11152953.3T patent/DK2319524T3/da active
- 2004-05-28 NZ NZ572940A patent/NZ572940A/en unknown
- 2004-05-28 NZ NZ578591A patent/NZ578591A/en unknown
- 2004-05-28 SI SI200431854T patent/SI1629088T1/sl unknown
- 2004-05-28 MX MXPA05012957A patent/MXPA05012957A/es active IP Right Grant
- 2004-05-28 EP EP11152953.3A patent/EP2319524B1/en active Active
- 2004-05-28 ES ES04785910T patent/ES2384622T3/es active Active
- 2004-05-28 CN CN200480021931.4A patent/CN101090729B/zh active Active
- 2004-05-28 EP EP04785910A patent/EP1629088B1/en active Active
- 2004-05-28 JP JP2006515056A patent/JP2007525196A/ja active Pending
- 2004-05-28 PL PL04785910T patent/PL1629088T3/pl unknown
- 2004-05-28 US US10/857,484 patent/US7622564B2/en active Active
- 2004-05-28 PT PT04785910T patent/PT1629088E/pt unknown
- 2004-05-28 AU AU2004263823A patent/AU2004263823B2/en active Active
- 2004-05-28 DK DK04785910.3T patent/DK1629088T3/da active
- 2004-05-28 RU RU2005141341/15A patent/RU2005141341A/ru not_active Application Discontinuation
- 2004-05-28 BR BRPI0410842A patent/BRPI0410842B8/pt active Search and Examination
- 2004-05-28 NZ NZ543840A patent/NZ543840A/en active IP Right Revival
- 2004-05-28 CA CA2526274A patent/CA2526274C/en active Active
- 2004-05-28 KR KR1020057022987A patent/KR101291787B1/ko active IP Right Grant
- 2004-05-28 WO PCT/US2004/017231 patent/WO2005014780A2/en active Application Filing
-
2005
- 2005-11-15 IL IL171966A patent/IL171966A/en active IP Right Grant
- 2005-11-22 NO NO20055508A patent/NO20055508L/no not_active Application Discontinuation
- 2005-11-24 IS IS8148A patent/IS2900B/is unknown
- 2005-11-28 ZA ZA200509606A patent/ZA200509606B/xx unknown
-
2006
- 2006-08-25 HK HK06109502.6A patent/HK1088635A1/xx unknown
-
2008
- 2008-12-17 AU AU2008258185A patent/AU2008258185B2/en active Active
-
2009
- 2009-09-17 US US12/561,832 patent/US8853364B2/en active Active
-
2011
- 2011-04-26 US US13/094,730 patent/US8278424B2/en active Active
-
2012
- 2012-04-10 CY CY20121100353T patent/CY1113044T1/el unknown
- 2012-09-28 US US13/631,699 patent/US20130041138A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113044T1 (el) | Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων | |
CY1113247T1 (el) | Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου | |
CY1114855T1 (el) | Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1 | |
CY1114069T1 (el) | Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 161p2f10b χρησιμα στη θεραπεια και ανιχνευση καρκινου | |
CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
DE60142615D1 (de) | Epitop-synchronisierung in antigen präsentierenden zellen | |
CY1106400T1 (el) | Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο | |
CY1113298T1 (el) | Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων | |
PT900380E (pt) | Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados | |
DK0970126T3 (da) | Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf | |
IL181218A0 (en) | Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer | |
WO2003033520A3 (en) | Anticancer vaccine and diganostic methods and reagents | |
TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
DK1573022T3 (da) | Nukleinsyre og tilsvarende protein betegnet 184P1E2, der er egnede til behandling og påvisning af cancer | |
DE60330004D1 (de) | Impfung mit immunisolierten und einen immunomodulator produzierenden zellen | |
CY1116795T1 (el) | Αντισωματα και σχετικα μορια που δεσμευονται στις πρωτεϊνες toy psca | |
CY1113332T1 (el) | Νουκλεϊκα οξεα και αντιστοιχες πρωτεϊνες με ονομασια 191p4d12(b) χρησιμα στην αγωγη και ανιχνευση καρκινου | |
AU2002223860A1 (en) | Nucleic acid vaccine comprising a fusion protein including an adjuvant sequence from a plant viral coat protein | |
CY1114674T1 (el) | Αντισωματα και σχετικα μορια που προσδενονται σε 24p4c12 πρωτεϊνες | |
MXPA05002520A (es) | Secuencia de acido nucleico 98p4b6 asociada con el cancer. | |
DK1553980T3 (da) | Nukleinsyre og tilsvarende protein med betegnelsen 238P1B2, egnet til behandling og påvisning af cancer | |
CY1113516T1 (el) | Νουκλεϊκο οξυ και αντιστοιχη πρωτεϊνη με ονομασια 158p1d7 χρησιμα στην αγωγη και ανιχνευση καρκινου ουροδοχου κυστης και αλλων καρκινων | |
CY1116170T1 (el) | Μεθοδος παρασκευης ανασυνδυασμενων αντισωματων εναντι ογκων | |
DE60318608D1 (de) | Ptprk-immunogenes peptid |